Free tool
FAERS Monitor: Elidel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021302 or its brand name (Elidel, Pimecrolimus). Reports on generic versions are filed under their own applications.
Reports
1,797
Serious
577
32% of reports
Hospitalization
199
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective266
- dermatitis atopic212
- pruritus209
- rash193
- product use in unapproved indication131
- dry skin111
- eczema104
- off label use103
- injection site pain82
- skin exfoliation80
- erythema77
- sleep disorder due to a general medical condition73
- pain67
- condition aggravated66
- product dose omission issue65
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 8 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 19 |
| 2012 | 5 |
| 2013 | 9 |
| 2014 | 13 |
| 2015 | 10 |
| 2016 | 15 |
| 2017 | 17 |
| 2018 | 40 |
| 2019 | 85 |
| 2020 | 102 |
| 2021 | 172 |
| 2022 | 200 |
| 2023 | 296 |
| 2024 | 274 |
| 2025 | 269 |
| 2026 | 242 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,362 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sleep disorder due to a general medical conditionSignal | 73 | 50.5 | 40.3 | 3,482 |
| dermatitis atopicSignal | 212 | 47.2 | 41.6 | 9,535 |
| eczemaSignal | 104 | 23.3 | 19.3 | 2,199 |
| skin exfoliationSignal | 80 | 11.1 | 9.0 | 728 |
| dry skinSignal | 111 | 9.7 | 8.1 | 867 |
| pruritusSignal | 209 | 6.4 | 5.6 | 957 |
| product use in unapproved indicationSignal | 131 | 6.2 | 5.2 | 571 |
| rashSignal | 193 | 5.2 | 4.5 | 661 |
| erythemaSignal | 77 | 4.4 | 3.5 | 200 |
| injection site painSignal | 82 | 3.1 | 2.5 | 118 |
| product dose omission issueSignal | 65 | 2.6 | 2.0 | 63 |
| condition aggravatedSignal | 66 | 2.5 | 2.0 | 61 |
| drug ineffectiveSignal | 266 | 2.4 | 2.1 | 222 |
| off label use | 103 | 1.4 | 1.1 | 11 |
| pain | 67 | 1.3 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.